The USFDA Grants Orphan Drug Designation to CT120 a Novel CAR T-Cell Therapy of IASO Biotherapeutics for Acute Lymphoblastic Leukemia
KEYPOINTS: The FDA has granted orphan drug designation (ODD) to CT120 for the treatment of acute lymphoblastic leukemia, a novel chimeric antigen…